{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T01:17:54Z","timestamp":1768699074659,"version":"3.49.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Grant-in-aid for Scientific Research","award":["25461580"],"award-info":[{"award-number":["25461580"]}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sport, Science, and Technology in Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Princess Takamatsunomiya Cancer Foundation"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","cancerletters.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.canlet.2016.11.021","type":"journal-article","created":{"date-parts":[[2016,11,25]],"date-time":"2016-11-25T22:46:43Z","timestamp":1480114003000},"page":"131-140","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Poly (ADP-ribose) polymerase inhibitors selectively induce cytotoxicity in TCF3-HLF\u2013positive leukemic cells"],"prefix":"10.1016","volume":"386","author":[{"given":"Jinhua","family":"Piao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiori","family":"Takai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Kamiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Inukai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanji","family":"Sugita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuma","family":"Ohyashiki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Delia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuko","family":"Masutani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuki","family":"Mizutani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7580-9184","authenticated-orcid":false,"given":"Masatoshi","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2016.11.021_bib1","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1111\/j.1349-7006.2007.00567.x","article-title":"PolyADP-ribosylation and cancer","volume":"98","author":"Miwa","year":"2007","journal-title":"Cancer Sci."},{"key":"10.1016\/j.canlet.2016.11.021_bib2","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/356356a0","article-title":"Role of poly(ADP-ribose) formation in DNA repair","volume":"356","author":"Satoh","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2016.11.021_bib3","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/nrc2342","article-title":"DNA repair pathways as targets for cancer therapy","volume":"8","author":"Helleday","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2016.11.021_bib4","doi-asserted-by":"crossref","first-page":"55117","DOI":"10.1074\/jbc.M404524200","article-title":"Involvement of poly(ADP-ribose) polymerase-1 and XRCC1\/DNA ligase III in an alternative route for DNA double-strand breaks rejoining","volume":"279","author":"Audebert","year":"2004","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.canlet.2016.11.021_bib5","doi-asserted-by":"crossref","first-page":"5526","DOI":"10.1093\/nar\/gkg761","article-title":"A\u00a0requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage","volume":"31","author":"El-Khamisy","year":"2003","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.canlet.2016.11.021_bib6","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2016.11.021_bib7","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2016.11.021_bib8","doi-asserted-by":"crossref","first-page":"4578","DOI":"10.1182\/blood-2010-01-265769","article-title":"The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in\u00a0vitro and in\u00a0vivo","volume":"116","author":"Weston","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2016.11.021_bib9","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1126\/science.1386162","article-title":"Fusion of the leucine zipper gene HLF to the E2A gene in human acute B-lineage leukemia","volume":"257","author":"Inaba","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.canlet.2016.11.021_bib10","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1101\/gad.6.9.1608","article-title":"Hlf, a novel hepatic bZIP protein, shows altered DNA-binding properties following fusion to E2A in t(17;19) acute lymphoblastic leukemia","volume":"6","author":"Hunger","year":"1992","journal-title":"Genes Dev."},{"key":"10.1016\/j.canlet.2016.11.021_bib11","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1126\/science.278.5340.1059","article-title":"Oncogenic transcription factors in the human acute leukemias","volume":"278","author":"Look","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.canlet.2016.11.021_bib12","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/sj.leu.2404496","article-title":"Hypercalcemia in childhood acute lymphoblastic leukemia: frequent implication of parathyroid hormone-related peptide and E2A-HLF from translocation 17;19","volume":"21","author":"Inukai","year":"2007","journal-title":"Leuk. Off. J. Leuk. Soc. Am."},{"key":"10.1016\/j.canlet.2016.11.021_bib13","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1182\/blood.V83.10.2970.2970","article-title":"Two types of genomic rearrangements create alternative E2A-HLF fusion proteins in t(17;19)-ALL","volume":"83","author":"Hunger","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2016.11.021_bib14","first-page":"322","article-title":"Establishment of a novel heterotransplantable acute lymphoblastic leukemia cell line with a t(17;19) chromosomal translocation the growth of which is inhibited by interleukin-3","volume":"5","author":"Ohyashiki","year":"1991","journal-title":"Leuk. Off. J. Leuk. Soc. Am."},{"key":"10.1016\/j.canlet.2016.11.021_bib15","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/sj.leu.2402120","article-title":"Expression of two types of E2A-HLF fusion proteins in YCUB-2, a novel cell line established from B-lineage leukemia with t(17;19)","volume":"15","author":"Takahashi","year":"2001","journal-title":"Leuk. Off. J. Leuk. Soc. Am."},{"key":"10.1016\/j.canlet.2016.11.021_bib16","first-page":"3192","article-title":"Establishment and molecular characterization of a novel leukemic cell line with Philadelphia chromosome expressing p230 BCR\/ABL fusion protein","volume":"55","author":"Wada","year":"1995","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2016.11.021_bib17","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.4340.4340","article-title":"Guide to leukemia-lymphoma cell lines on CD","volume":"106","author":"Drexler","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2016.11.021_bib18","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/ajh.21738","article-title":"A\u00a0specific linkage between the incidence of TP53 mutations and type of chromosomal translocations in B-precursor acute lymphoblastic leukemia cell lines","volume":"85","author":"Inukai","year":"2010","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.canlet.2016.11.021_bib19","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1038\/nm.3993","article-title":"Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors","volume":"21","author":"Esposito","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2016.11.021_bib20","doi-asserted-by":"crossref","first-page":"5389","DOI":"10.1158\/0008-5472.CAN-09-4716","article-title":"Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells","volume":"70","author":"Gottipati","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2016.11.021_bib21","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1101\/gad.13.20.2633","article-title":"XRCC3 promotes homology-directed repair of DNA damage in mammalian cells","volume":"13","author":"Pierce","year":"1999","journal-title":"Genes Dev."},{"key":"10.1016\/j.canlet.2016.11.021_bib22","doi-asserted-by":"crossref","first-page":"34091","DOI":"10.1074\/jbc.C400139200","article-title":"Microcephalin is a DNA damage response protein involved in regulation of CHK1 and BRCA1","volume":"279","author":"Xu","year":"2004","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.canlet.2016.11.021_bib23","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/nature03482","article-title":"DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis","volume":"434","author":"Bartkova","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2016.11.021_bib24","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/nature03485","article-title":"Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions","volume":"434","author":"Gorgoulis","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2016.11.021_bib25","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/ng0997-96","article-title":"Clustering of missense mutations in the ataxia-telangiectasia gene in a sporadic T-cell leukaemia","volume":"17","author":"Vorechovsky","year":"1997","journal-title":"Nat. Genet."},{"key":"10.1016\/j.canlet.2016.11.021_bib26","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1073\/pnas.050400997","article-title":"Mantle cell lymphoma is characterized by inactivation of the ATM gene","volume":"97","author":"Schaffner","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2016.11.021_bib27","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0140-6736(98)10117-4","article-title":"Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukaemia","volume":"353","author":"Stankovic","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2016.11.021_bib28","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1038\/sj.onc.1202692","article-title":"Mutations in the RAD54 recombination gene in primary cancers","volume":"18","author":"Matsuda","year":"1999","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2016.11.021_bib29","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.1038\/sj.onc.1202691","article-title":"Mutations of a novel human RAD54 homologue, RAD54B, in primary cancer","volume":"18","author":"Hiramoto","year":"1999","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2016.11.021_bib30","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1093\/hmg\/11.18.2189","article-title":"Defects in homologous recombination repair in mismatch-repair-deficient tumour cell lines","volume":"11","author":"Mohindra","year":"2002","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.canlet.2016.11.021_bib31","doi-asserted-by":"crossref","first-page":"638","DOI":"10.3324\/haematol.2008.001933","article-title":"Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes","volume":"94","author":"Gaymes","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.canlet.2016.11.021_bib32","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1158\/1535-7163.MCT-09-0142","article-title":"Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity","volume":"8","author":"Horton","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.canlet.2016.11.021_bib33","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.bbadis.2014.12.001","article-title":"BRCA1, PARP1 and gammaH2AX in acute myeloid leukemia: role as biomarkers of response to the PARP inhibitor olaparib","volume":"1852","author":"Faraoni","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.canlet.2016.11.021_bib34","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1158\/1078-0432.CCR-14-2572","article-title":"Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing\u00a0program","volume":"21","author":"Smith","year":"2015","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.canlet.2016.11.021_bib35","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1158\/1535-7163.MCT-14-0276","article-title":"The combination of the PARP inhibitor rucaparib and 5FU is an effective strategy for treating acute leukemias","volume":"14","author":"Falzacappa","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.canlet.2016.11.021_bib36","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1182\/blood-2009-09-244673","article-title":"Aberrant induction of LMO2 by the E2A-HLF chimeric transcription factor and its implication in leukemogenesis of B-precursor ALL with t(17;19)","volume":"116","author":"Hirose","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2016.11.021_bib37","doi-asserted-by":"crossref","first-page":"5718","DOI":"10.1038\/sj.onc.1204591","article-title":"E2A-HLF usurps control of evolutionarily conserved survival pathways","volume":"20","author":"Seidel","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2016.11.021_bib38","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.1158\/0008-5472.CAN-10-3119","article-title":"Bcl-2 inhibits nuclear homologous recombination by localizing BRCA1 to the endomembranes","volume":"71","author":"Laulier","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2016.11.021_bib39","doi-asserted-by":"crossref","first-page":"9404","DOI":"10.1158\/0008-5472.CAN-08-0861","article-title":"AKT1 inhibits homologous recombination by inducing cytoplasmic retention of BRCA1 and RAD51","volume":"68","author":"Plo","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2016.11.021_bib40","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/leu.2010.253","article-title":"The E2A-HLF oncogenic fusion protein acts through Lmo2 and Bcl-2 to immortalize hematopoietic progenitors","volume":"25","author":"de Boer","year":"2011","journal-title":"Leuk. Off. J. Leuk. Soc. Am."},{"key":"10.1016\/j.canlet.2016.11.021_bib41","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1200\/JCO.2008.19.7681","article-title":"Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies","volume":"27","author":"Kummar","year":"2009","journal-title":"J.\u00a0Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.canlet.2016.11.021_bib42","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1158\/1078-0432.CCR-06-3039","article-title":"ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models","volume":"13","author":"Donawho","year":"2007","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.canlet.2016.11.021_bib43","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.canlet.2016.11.021_bib44","doi-asserted-by":"crossref","first-page":"17079","DOI":"10.1073\/pnas.0806092105","article-title":"High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs","volume":"105","author":"Rottenberg","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2016.11.021_bib45","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1007\/s10637-011-9682-9","article-title":"Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study","volume":"30","author":"Samol","year":"2012","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.canlet.2016.11.021_bib46","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/bjc.2011.8","article-title":"A\u00a0phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours","volume":"104","author":"Khan","year":"2011","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2016.11.021_bib47","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/bjc.2014.345","article-title":"Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours","volume":"111","author":"Del Conte","year":"2014","journal-title":"Br. J. Cancer"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383516307091?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383516307091?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,27]],"date-time":"2020-09-27T14:24:57Z","timestamp":1601216697000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383516307091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":47,"alternative-id":["S0304383516307091"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2016.11.021","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Poly (ADP-ribose) polymerase inhibitors selectively induce cytotoxicity in TCF3-HLF\u2013positive leukemic cells","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2016.11.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}